企業プロフィール
Argenx 株価・ニュース・カタリスト
- ティッカー:
- ARGX
- 取引所:
- NASDAQ
- セクター:
- Antibody Drugs
- 所在地:
- Ghent, Belgium and listed in the U
株価パフォーマンス
987.84 USD (+16.04%)
終値
最終更新: 2026年8月17日
49.9B USD
時価総額
株価変動の要因
Following the latest company update, “argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis”, ARGX closed up 16.0% at $987.84 on Aug 17, 2026. The move occurred in the trading session associated with this clinical readout update.
企業概要
Global Immunology Company
Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional indications such as primary immune thrombocytopenia.
VYVGART Expansion Strategy
The company is expanding VYVGART into ocular myasthenia gravis, autoimmune myositis, primary immune thrombocytopenia, Sjögren’s disease, and Graves’ disease. VYVGART Hytrulo, the subcutaneous formulation, broadens the franchise through more convenient administration.
Global Commercial Franchise
VYVGART is commercialized across multiple regions and formulations, with the expanded U.S. label covering all adult gMG serotypes. The franchise provides argenx with an established commercial organization that can support additional indications and future immunology assets.
Empasiprubart as a Second Franchise
Empasiprubart, a complement C2-targeting antibody, represents argenx’s second potential pipeline-in-a-product. It is being studied in multifocal motor neuropathy, CIDP, delayed graft function, and combination therapy with VYVGART in gMG.
Earlier Immunology Pipeline
Additional programs include next-generation FcRn candidates ARGX-213 and ARGX-124, MuSK agonist adimanebart, anti-IgA antibody ARGX-121, and other candidates emerging from the company’s Immunology Innovation Program.
Vision 2030 Framework
Argenx’s long-term strategy targets 50,000 patients treated globally, ten labeled indications, and five pipeline candidates in registrational development by 2030. The framework links continued VYVGART expansion with the creation of multiple independent immunology franchises.
今後のカタリスト
- Topline data from the registrational ALKIVIA study of VYVGART in autoimmune myositis are expected in the third quarter of 2026.
- Topline data from the registrational EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in the fourth quarter of 2026.
- Topline results from the ADVANCE-NEXT study in primary ITP are expected in the first half of 2027, followed by UNITY data in Sjögren’s disease in the second half of 2027.
- A VYVGART SC autoinjector is expected to launch across all approved indications in 2027.
- A registrational study of adimanebart in congenital myasthenic syndromes, a Phase 2 study of ARGX-121 in IgA nephropathy, and Phase 1 studies of ARGX-118 and ARGX-125 are planned to advance during 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。